1. Introduction {#sec1}
===============

Coronaviruses (CoVs) are members of the family *Coronaviridae* in the order *Nidovirales* and the genus *Coronavirus* ([@bib1]). CoVs are enveloped, single-stranded, positive-sense RNA viruses that have the largest genome among RNA viruses (\~32 kb) ([@bib36]) and are widespread and naturally infect a variety of species. Currently, six CoVs have been identified that predominantly cause respiratory and central nervous system (CNS) pathologies in humans. HCoV-OC43 and HCoV-229E usually cause common colds during the winter and early spring ([@bib22]), whereas HCoV-NL63 is responsible for causing croup in children and results in more severe clinical features than those of HCoV-OC43 or HCoV-229E ([@bib4]; [@bib13]; [@bib48]). HCoV-HKU1 is associated with bronchiolitis and pneumonia ([@bib52], [@bib53]). In 2003, an outbreak of severe acute respiratory syndrome (SARS), a lethal zoonotic CoV infection, was reported in China and associated with SARS-CoV ([@bib21]). In 2012, a SARS-like disease emerged that resulted in a mortality rate of 30%, the causative agent of which was identified as Middle East respiratory syndrome CoV (MERS-CoV) ([@bib14]; [@bib31]). Despite their status as infectious respiratory pathogens, CoVs can also damage the CNS and cause neurological diseases ([@bib2]; [@bib3]; [@bib6]; [@bib15]; [@bib32]; [@bib33]), with HCoV-OC43, HCoV-229E, and SARS-CoV detected in the cerebrospinal fluid of patients with multiple sclerosis ([@bib3]; [@bib6]; [@bib15]). Recently, severe neurological syndromes were identified as associated with MERS-CoV ([@bib2]), SASR-CoV reportedly exhibits neuroinvasive properties in the CNS of mice ([@bib33]), and HCoV-OC43 is associated with fatal encephalitis ([@bib32]). Therefore, CoVs are thought to be responsible for CNS pathologies in a way similar to other known neuroinvasive viruses, such as measles virus, human immunodeficiency virus, and herpes virus ([@bib20]). Until recently, little was known about the process and dynamics of HCoV infection in the CNS, and no effective drugs are currently available for treating patients with these infections; therefore, easily observable animal models are required to understand viral replication and investigate potential therapeutic strategies.

Conventional assays that examine host--pathogen interactions are indispensable for demonstrating the processes of pathogen infection and dissemination. Mouse models are commonly used to study viral replication and dissemination and test potential antiviral drugs; however, this conventional approach has various limitations. The experimental animals must be anatomised at multiple time points to study the sites of infection and quantify pathogen titer, thus requiring a large number of animals. Moreover, these approaches cannot monitor the real-time spatial and temporal progression of infection in the same animal. Bioluminescence imaging (BLI) is a powerful optical technique for the molecular imaging of infectious diseases and therapies. *In vivo* BLI techniques have emerged as powerful complements to conventional assays used for studying pathogen replication and dissemination ([@bib16]; [@bib27]). Renilla luciferase (Rluc), among the most widely distributed and commonly used luciferase enzymes for *in vivo* imaging, is purified from the marine organism *Renilla reniformis* (sea pansy), which exhibits blue-green bioluminescence when catalysis is stimulated. Rluc is ATP-independent and oxidizes coelenterazine to generate bioluminescence ([@bib26]). Upon oxidation by Rluc *in vitro*, coelenterazine produces blue light with a peak emission at \~480 nm ([@bib28]). Unlike other luciferases, Rluc has smaller components, high specificity and sensitivity, and can be genetically fused with other proteins, which is particularly useful when investigating pathogens with large genome restrictions ([@bib49]).

Non-invasive imaging methods that can monitor viral replication in living animals are more convenient for the temporal and spatial investigation of viral dissemination and pathogenesis than conventional assays. Moreover, the same living animal can be monitored at different time points, thereby reducing the number of animals required to generate sufficient data. The use of recombinant viruses tagged with luciferase is less well studied but becoming increasingly popular. Previously, we used a recombinant Rluc-expressing virus based on the HCoV-OC43 backbone (rOC43-ns2DelRluc) to screen anti-CoV agents and antiviral host factors ([@bib42]). HCoV-OC43 belongs to the genus *Betacoronavirus* along with severe SARS-CoV and MERS-CoV ([@bib30]; [@bib43]) and in which important replication-related genes are conserved, including *3Clpro*, *RdRp*, and *RNA helicase* ([@bib47]; [@bib51]). HCoV-OC43 causes only mild infection in humans but can cause severe CNS pathology in suckling mice and be manipulated in biosafety level 2 facilities. Moreover, rOC43-ns2DelRluc shows robust growth kinetics and identical virulence to the wild-type virus *in vivo*.

Chloroquine (CQ), a 4-aminoquinoline approved by the Food and Drug Administration to treat malaria, has long been prescribed prophylactically to pregnant women at risk of exposure to *Plasmodium* parasites ([@bib23]). CQ reportedly exhibits antimalarial, anti-inflammatory, and antiviral activities, with *in vitro* efficacy against several viruses, including CoVs ([@bib50]); however, real-time data concerning its *in vivo* distribution during viral infection and anti-CoV activity in living animals remains limited.

Here, we utilized rOC43-ns2DelRluc to study the timing of HCoV replication and dissemination in the CNS of mice and verified CQ as a CoV inhibitor *in vivo* by using non-invasive BLI in living mice. Our study provides new insights into CoV replication and dissemination in the CNS and offers a convenient and valuable method for identifying anti-HCoV drugs capable of treating neurological symptoms.

2. Materials and methods {#sec2}
========================

2.1. Cells and antibodies {#sec2.1}
-------------------------

BHK-21 cells were grown in Dulbecco\'s modified Eagle medium (Gibco, Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum (Gibco) and 2 mM L-glutamine (Gibco) at 37 °C and 5% CO~2~. Anti-β-actin (4970s) rabbit monoclonal antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-rabbit (5230--0403) and anti-mouse (5230--0347) IgG (H + L) were purchased from KPL (Gaithersburg, MD, USA). Anti-Rluc (ab185925) rabbit monoclonal and goat anti-rabbit IgG (ab150077) antibodies were purchased from Abcam (Cambridge, UK). Anti-OC43-N mouse polyclonal antibodies were prepared in our laboratory, and goat anti-mouse IgG (A28175) secondary antibodies were purchased from Life Technologies (Carlsbad, CA, USA). Anti-NeuN mouse monoclonal (Mab377) antibodies were purchased from Millipore (Billerica, MA, USA), and goat anti-mouse IgG (H + L) (A11031) secondary antibodies were purchased from Life Technologies. Anti-microtubule-associated protein 2 (MAP2; ab5392) chicken polyclonal antibodies and goat anti-chicken (ab150176) polyclonal antibodies were purchased from Abcam.

2.2. Animal experiments {#sec2.2}
-----------------------

BALB/c and C57BL/6 mice were purchased from the Animal Care Centre, Chinese Academy of Medical Science (Beijing, China). The study protocol was approved by the Committee on the Ethics of Animal Experiments of the Chinese Center for Disease Control and Prevention. Pathogen-free mice were housed and used in accordance with the guidelines of the Chinese Regulations for the Administration of Affairs Concerning Experimental Animals. BALB/c (12-days old) or C57BL/6 (7-days old) mice were intracerebrally or intranasally inoculated with rOC43-ns2DelRluc or HCoV-OC43-wild-type (WT) for subsequent assays.

2.3. Tissue homogenization {#sec2.3}
--------------------------

Whole brain, spinal cord, spleen, heart and blood were collected from rOC43-ns2DelRluc-infected mice, homogenized in phosphate-buffered saline (PBS) using a FastPrep instrument (MP Biomedical, Strasbourg, France) and centrifuged at 14,000 rpm for 10 min at 4 °C to remove tissue debris. The supernatant was collected and aliquoted for further study.

2.4. Western blot {#sec2.4}
-----------------

Brain and spinal homogenates were separated by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes, which were blocked with 5% skim milk at room temperature for 2 h and incubated with anti-OC43-N mouse polyclonal or anti-β-actin antibodies at 4 °C overnight. After washing with PBS with Tween-20, the membranes were incubated with anti-mouse IgG (1:10,000; KPL) or anti-rabbit IgG (1:5000; KPL) at room temperature for 1 h. Blots were scanned to detect infrared fluorescence using the Odyssey infrared imaging system (Li-Cor Biosciences, Lincoln, NE, USA).

2.5. RNA isolation and quantitative reverse transcription polymerase chain reaction (qRT-PCR) {#sec2.5}
---------------------------------------------------------------------------------------------

Total RNA was isolated from the tissue-homogenate supernatants of virus-infected mice using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and the relative amount of viral genomic rOC43-ns2DelRluc RNA was quantified using qRT-PCR, as described previously ([@bib34]) and the following primers and probe: forward, 5′-GCTCAGGAAGGTCTGCTCC-3′; reverse, 5′-TCCTGCACTAGAGGCTCTGC-3′; and the probe FAM-TTCCAGATCTACTTCGCGCACATCC-TAMRA.

2.6. Viral titration {#sec2.6}
--------------------

The rHCoVs-OC43 50% tissue culture infectious dose (TCID~50~) was determined by indirect immunofluorescence assay (IFA) according to a previously described method ([@bib40]). Briefly, BHK-21 cells in 96-well plates were inoculated with serial 10-fold dilutions of virus, and virus-infected cells were incubated with anti-OC43-N mouse polyclonal antibodies at 72-h post -infection. Goat anti-mouse IgG (A28175) antibodies were used as the secondary antibody.

2.7. Immunofluorescence assay {#sec2.7}
-----------------------------

The brain and spinal cord dissected from rOC43-ns2DelRluc-infected mice and control mice at 6-days post-infection (dpi) were fixed in 10% neutral-buffered formalin, embedded in paraffin, and routinely sectioned to a thickness of \~5 μm. The sections were then permeabilized with 0.3% Triton X-100 in PBS for 30 min, blocked with 5% bovine serum albumin for 1 h at room temperature, and incubated with primary antibodies, including anti-Rluc rabbit monoclonal antibodies, anti-NeuN antibodies and anti-MAP2 antibodies, at 4 °C overnight. Sections were then incubated with secondary antibodies, including Alexa Fluor 488-conjugated goat anti-rabbit (ab150077), Alexa Fluor 568-conjugated goat anti-mouse IgG (H + L) and Alexa Fluor 596-conjugated goat anti-chicken polyclonal antibodies at 37 °C for 1 h. After staining with 1 μg/mL 4′,6-diamidino-2-phenylindole (Sigma-Aldrich, St. Louis, MO, USA) for 30 min, the sections were covered with Permount, and images were captured by Operetta (PerkinElmer, Waltham, MA, USA) with Columbus software or by a Leica TCS SP8 confocal microscope with LAS software (Leica Biosystems, Wetzlar, Germany).

2.8. BLI analysis {#sec2.8}
-----------------

rOC43-ns2DelRluc replication in mice was evaluated by BLI with an In Vivo F Pro (Bruker Daltonik, Bremen, Germany). Prior to imaging, rOC43-ns2DelRluc-infected mice were injected intraperitoneally with Renilla luciferase substrate (20 μg/g; Promega, Madison, WI, USA) and anaesthetized with isoflurane. After 5 min, mice were placed on a light-tight camera box stage under continuous anesthesia, imaged (acquisition time: 4 min), and the signals were quantified using Bruker molecular imaging software (Bruker).

2.9. Statistical analysis {#sec2.9}
-------------------------

All graphs were produced using Prism 5.0 software (GraphPad Software, San Diego, CA, USA), and results are expressed as the mean ± standard error of the mean. Statistical analysis were performed using SPSS (v.21.0; IBM Corp., Armonk NY, USA). Differences were considered statistically significant at *P* \< 0.05.

3. Results {#sec3}
==========

3.1. Intranasal rOC43-ns2DelRluc inoculation is fatal to suckling mice {#sec3.1}
----------------------------------------------------------------------

Previously, we constructed several recombinant Rluc-expressing HCoV-OC43-reporter viruses. One reporter virus (rOC43-ns2DelRluc) in which the *ns2* gene was replaced by Rluc showed robust growth kinetics similar to those of HCoV-OC43-WT and high stability after multiple passages *in vitro*. Additionally, rOC43-ns2DelRluc (100 TCID~50~) showed pathogenicity in BALB/c mice, which exhibited neurological symptoms identical to those caused by the parental virus after intracerebral inoculation ([@bib42]).

Viral replication *in vivo* depends on the genetic backgrounds of both the virus and its host. Previous studies reported that inbred BALB/c and C57BL6 mice are susceptible to HCoV-OC43 infection ([@bib17]; [@bib18]; [@bib35]). Therefore, these two mouse strains were infected with 10^4^ TCID~50~ of rOC43-ns2DelRluc or HCoV-OC43-WT by intranasal inoculation in order to determine its infection of the respiratory tract *in vivo*. As expected, both strains presented typical symptoms of advanced disease (twitching limbs and humped back) after inoculation with rOC43-ns2DelRluc or HCoV-OC43-WT. Intranasal rOC43-ns2DelRluc inoculation led to 100% mortality in both strains, with most mice dying at 7 dpi, similar to those infected with HCoV-OC43-WT ([Fig. 1](#fig1){ref-type="fig"} A and C). Additionally, both mouse strains infected with rOC43-ns2DelRluc showed reduced body weight, similar to those infected with HCoV-OC43-WT ([Fig. 1](#fig1){ref-type="fig"}B and D). According to a previous report ([@bib18]), C57BL/6 mice, especially those \>15-days old, are more sensitive to HCoV-OC43 than BALB/c. However, in the present study, we found that both BALB/c or C57BL/6 suckling mice (\<12-days old) infected with HCoV-OC43 at a dose of 10^4^ TCID~50~ showed 100% mortality and similar sensitivity. These results showed that rOC43-ns2DelRluc infection resulted in severe encephalitis and neurological symptoms in both mouse strains, suggesting that rOC43-ns2DelRluc can be used as an infection model for simulating HCoV-OC43-WT CNS infection *in vivo*.Fig. 1**rOC43-ns2DelRluc is fatal in suckling mice.** (A and B) BALB/c mice and (C and D) C57BL/6 mice were intranasally infected with 10^4^ TCID~50~ of rOC43-ns2DelRluc (*n* = 20/group). Weight loss (B and D) and survival (A and C) were monitored daily.Fig. 1

3.2. rOC43-ns2DelRluc replication and dissemination in mice with different genetic backgrounds {#sec3.2}
----------------------------------------------------------------------------------------------

To confirm these observations and the dissemination of the recombinant virus, the viral load in different tissues was determined using an IFA in BHK-21 cells or real-time qRT-PCR at 6 dpi via intranasal inoculation of 10^4^ TCID~50~ of rOC43-ns2DelRluc. In line with the symptoms, we detected high viral titers in the brains and spinal cords of both mouse strains ([Fig. 2](#fig2){ref-type="fig"} A, upper), whereas low viral RNA levels were detected in the hearts and spleen, and extremely low levels were detected in the blood ([Fig. 2](#fig2){ref-type="fig"}A, lower), consistent with previous reports on HCoV-OC43-WT ([@bib11]; [@bib18]). Immunostaining of brain and spinal cord sections from mice that underwent intracerebral infection confirmed the presence of rOC43-ns2DelRluc ([Fig. 2](#fig2){ref-type="fig"}B), with Rluc detected in neuron cells labeled with MAP2 or NeuN in several areas of the CNS in both mouse strains ([Fig. 2](#fig2){ref-type="fig"}C and D). These results suggested rOC43-ns2DelRluc as a promising candidate for BLI in both mouse strains.Fig. 2**Replication and dissemination of rOC43-ns2DelRluc in mice with different genetic backgrounds.** (A) Detection of rOC43-ns2DelRluc in different tissues. Mice were inoculated intranasally with 10^4^ TCID~50~ rOC43-ns2DelRluc and sacrificed at 6 dpi. Tissue supernatants were analyzed for viral load by IFA (upper) in BHK-21 cells or real-time qRT-PCR (lower). Data represent three independent experiments and are shown as the mean ± standard deviation. (B) Immunofluorescence staining of infected and mock-infected mouse brains and spinal cords. (C and D) Double-staining for Rluc and neuron cells in brain and spinal cord sections. Mice were inoculated intranasally with 10^4^ TCID~50~ rOC43-ns2DelRluc and sacrificed at 6 dpi. Brain and spinal cord tissues were analyzed using Operetta (PerkinElmer) with Columbus software (B) or a Leica TCS SP8 confocal microscope with LAS software (C and D). Representative graphs are shown of various brain and spinal cord sections from rOC43-ns2DelRluc-infected BALB/c and C57BL/6 mice.Fig. 2

3.3. BLI of rOC43-ns2DelRluc-infected mice {#sec3.3}
------------------------------------------

To perform BLI of rOC43-ns2DelRluc *in vivo*, BALB/c and C57BL/6 mice were intranasally inoculated with 10^4^ TCID~50~ of rOC43-ns2DelRluc or HCoV-OC43-WT, monitored over time, and bioluminescence intensity was determined ([Fig. 3](#fig3){ref-type="fig"} ). At 6 dpi, signals were observed in the brain and spinal cord when the dorsal side of BALB/c mice was imaged ([Fig. 3](#fig3){ref-type="fig"}A), whereas no signals were detected in mice infected with HCoV-OC43-WT (data not shown). Moreover, when the ventral side of BALB/c mice was imaged, no replication was observed ([Fig. 3](#fig3){ref-type="fig"}A and B). Surprisingly, no signals were detected in the brains of C57BL/6 mice until their death at 7 dpi; however, by this point we had removed their fur, which might have affected photon transmission from both the dorsal and ventral sides ([Fig. 3](#fig3){ref-type="fig"}A and B). Because we confirmed rOC43-ns2DelRluc replication in various mice from both strains, the lack of signals in C57BL/6 mice could have been due to the low penetration and bioavailability of the Rluc substrate in the mice rather than a low viral titer in the CNS. These results indicted that BLI was readily visualized and could be used to quantify rOC43-ns2DelRluc replication and dissemination in the CNS of living BALB/c mice, suggesting this virus as a potential candidate for real-time imaging following inoculation.Fig. 3**BLI of rOC43-ns2DelRluc in mice with different genetic backgrounds.** (A) BLI of the dorsal and ventral sides of mice with different genetic backgrounds. BALB/c and C57BL/6 mice were intranasally infected with 10^4^ TCID~50~ rOC43-ns2DelRluc, and BLI was performed at 6 dpi by intraperitoneal injection of Rluc substrate and capture of photon emission using an In Vivo F Pro system. Representative graphs are shown of the dorsal and ventral views. (B) Comparison of BLI from different sides of mice with different genetic backgrounds. Data represent three independent experiments and are shown as the mean ± standard deviation.Fig. 3

3.4. Real-time imaging of rOC43-ns2DelRluc in mice {#sec3.4}
--------------------------------------------------

We then used BLI to study the time course of rOC43-ns2DelRluc replication and dissemination. Briefly, individual BALB/c mice were either inoculated intracerebrally with 100 TCID~50~ or intranasally with 10^4^ TCID~50~ of rOC43-ns2DelRluc and monitored over time. Two days after intracerebral inoculation, signals were apparent in the brain from the dorsal side of the mice ([Fig. 4](#fig4){ref-type="fig"}A and [S1](#appsec1){ref-type="sec"}), and at 4 dpi, the signals detected in the brain became more dispersed, and additional signals were detected in the spine ([Fig. 4](#fig4){ref-type="fig"}A and [S1](#appsec1){ref-type="sec"}). Simultaneously, infected BALB/c mice exhibited severe symptoms typical of advanced disease (twitching limbs) and died soon thereafter. Following intranasal inoculation, signals emanating from the brain were observed at 3 dpi and peaked at 7 dpi, whereas signals emanating from the spinal cord were detected at 6 dpi ([Fig. 4](#fig4){ref-type="fig"}F and [S1](#appsec1){ref-type="sec"}), and the mice died at 7 dpi. To verify whether there was a direct correlation between intensity and viral titer, BALB/c mice intracerebrally or intranasally inoculated with rOC43-ns2DelRluc were sacrificed at different time points. Viral replication determined by indirect IFA in the brains and spinal cords revealed a good correlation between relative viral load and bioluminescence intensity ([Fig. 4](#fig4){ref-type="fig"} B, D, G, and I), with a high level of correlation between the two variables ([Fig. 4](#fig4){ref-type="fig"}C, E, H, and J), particularly in the intracerebral-infection group ([Fig. 4](#fig4){ref-type="fig"}C). This result confirmed the efficacy of BLI for assessing viral load in rOC43-ns2DelRluc-infected mice. Western blot analysis ([Fig. 4](#fig4){ref-type="fig"}K and L) further validated the time course of rOC43-ns2DelRluc replication in the brain and spinal cord. These findings indicated that BLI revealed the temporal and spatial progression of HCoV-OC43 replication in live mice and provided a non-invasive method for sensitively quantifying small differences.Fig. 4**BLI of the spatial and temporal progression of rOC43-ns2DelRluc infection.** BLI of BALB/c mice after intracerebral (A) or intranasal (F) infection with rOC43-ns2DelRluc. BALB/c mice underwent intracerebral (100 TCID~50~) or intranasal (10^4^ TCID~50~) inoculation on day 0 with rOC43-ns2DelRluc, and BLI was performed daily by intraperitoneal injection of Rluc substrate and capture of photon emission using an In Vivo F Pro system. Representative BLI images are shown. (B--E) Data correspond to the time course after intracerebral infection. Luciferase activity was quantified using the In Vivo F Pro system, and viral titer was determined by indirect IFA of brain (B) and spinal cord (D) tissue at the indicated time points. The R^2^ and *P*-values for the linear regression analysis of brain (C) and spinal cord (E) tissue are indicated on each graph. (G--J) Data correspond to the time course after intranasal infection. Luciferase activity was quantified using the In Vivo F Pro system, and viral titer was determined by indirect IFA of brain (G) and spinal cord (I) tissue at the indicated time points. The R^2^ and *P*-values for the linear regression analysis of brain (H) and spinal cord (J) tissue are indicated on each graph. Data represent three independent experiments and are shown as the mean ± standard deviation. Western blot analysis of rOC43-ns2DelRluc replication after intracerebral (K) or intranasal (L) inoculation.Fig. 4

3.5. Real-time imaging of antiviral agents *in vivo* {#sec3.5}
----------------------------------------------------

To verify whether BLI of rOC43-ns2DelRluc-infected mice could be used to test the efficiency of antiviral drugs *in vivo*, CQ was administered to mice 2 h before viral inoculation (day 0; 30 mg/kg) and then administered daily according to a previous study of HCoV-OC43-WT ([@bib19]). Mice were intracerebrally infected with 100 TCID~50~ of rOC43-ns2DelRluc, and bioluminescence intensity was measured daily ([Fig. 5](#fig5){ref-type="fig"} ). No signals were detected in mice treated with CQ, and all of them survived ([Fig. 5](#fig5){ref-type="fig"}A, lower), whereas all mice receiving PBS displayed increased bioluminescence and died ([Fig. 5](#fig5){ref-type="fig"}A; upper), demonstrating a significant difference relative to the individual controls ([Fig. 5](#fig5){ref-type="fig"}B and C). Western blot analysis confirmed the difference in rOC43-ns2DelRluc replication between mice treated with or without CQ ([Fig. 5](#fig5){ref-type="fig"}D and E). These results showed that rOC43-ns2DelRluc-infected mice could be used as a sensitive *in vivo* tool for testing the efficiency of antiviral drugs against HCoV-OC43 and compounds against a broad-spectrum of CoVs, particularly severe SARS-CoV and MERS-CoV.Fig. 5**BLI of rOC43-ns2DelRluc allows evaluation of antiviral therapeutics in living mice.** (A) BLI of BALB/c mice treated with or without CQ after rOC43-ns2DelRluc inoculation. Mice infected intracerebrally with 100 TCID~50~ of rOC43-ns2DelRluc were untreated (upper panel) or treated (lower panel) with CQ (30 mg/kg) daily, followed by daily BLI by intraperitoneal injection of Rluc substrate and capture of photon emission using an In Vivo F Pro system. A representative BLI image of one mouse is shown. Comparative time course of BLI of brain (B) and spinal cord (C) tissue of mice treated with or without CQ after rOC43-ns2DelRluc inoculation. Luciferase activity was quantified using an In Vivo F Pro system. Data represent three independent experiments and are shown as the mean ± standard deviation. Western blot analysis of brain (D) and spinal cord (E) tissue from BALB/c mice treated with or without CQ after rOC43-ns2DelRluc inoculation.Fig. 5

4. Discussion {#sec4}
=============

CoVs, which cause respiratory diseases, have also been associated with neurological complications ([@bib2]; [@bib3]; [@bib6]; [@bib15]; [@bib33]), with HCoV-OC43 even causing fatal encephalitis ([@bib17]; [@bib18]; [@bib32]); however, the mechanisms responsible for their dissemination and penetration in the host CNS remain unclear. Therefore, easily observable, living animal models are required to identify the mechanisms of HCoV infection in the CNS and enable the development of antiviral drugs for treating and preventing CoV infection and their associated severe CNS pathologies. Here, we used BLI to monitor HCoV-OC43 infection in real-time using the rOC43-ns2DelRluc reporter protein as a direct correlate of viral titer. We confirmed our previous observation by demonstrating that rOC43-ns2DelRluc possesses critical neurotropic and neuroinvasive properties after infection via the respiratory tract. Rluc, which is smaller than Firefly luciferase (Fluc), is useful for producing genetic fusions with other proteins, particularly for viruses with large genomes, such as like CoVs. Replacing *ns2* with Rluc did not impair viral-replication kinetics, and we observed robust Rluc activity. Moreover, Rluc expression levels correlated well with viral replication in the infected CNS, revealing the dynamic infection process. Therefore, our results demonstrated that BALB/c mice infected with rOC43-ns2DelRluc could be a promising animal model for testing the efficacy of antiviral drugs to treat neurological symptoms. As expected, CQ, a widely used drug with well-known antimalarial effects, strongly attenuated HCoV-OC43 replication in the brain and prevented the infection from spreading to the spinal cord, consistent with a previous study ([@bib19]).

Acute respiratory syndrome caused by viral infection poses a serious threat to public health due to high morbidity and mortality rates ([@bib46]). Notably, extra-pulmonary symptoms have been described for respiratory viruses such as influenza virus, human respiratory syncytial virus, and human metapneumovirus, accompanied by neurological complications ([@bib10]; [@bib29]; [@bib44]). Different mouse models have been established that are susceptible to these viruses ([@bib7]; [@bib25]; [@bib39]; [@bib55]); however, these models do not develop severe CNS pathologies. [@bib24] used BLI to study neurotropic flaviviruses, which can severely damage the central and peripheral nervous systems, showing that viral RNA measured by qRT-PCR directly correlated with Rluc bioluminescence intensity in intracranially inoculated mice. HCoV-OC43, a respiratory CoV, could be a powerful tool for gaining new insights into the neurological manifestations and neurotropic mechanisms of other respiratory viruses. In the present study, our data demonstrated that rOC43-ns2DelRluc levels reflected HCoV-OC43-WT replication in the brain and its spread to the spinal cord of living mice, with bioluminescence intensity directly correlating with viral loads as measured by IFA and western blot and consistent with previous studies ([@bib11]; [@bib17]).

Preclinical animal models that mimic the human pathogenesis of Beta-CoV infection are still urgently needed to develop vaccines and therapies. BLI has emerged as a powerful tool for studying animal models of viral disease, thereby enabling real-time study of viral infection, host immune responses, and the efficacy of intervention strategies *in vivo*. Two animal models using BLI have been reported for studying the relationship between CoVs and their hosts and identifying anti-CoV agents ([@bib12]; [@bib38]). [@bib38] constructed a recombinant virus expressing Fluc based on mouse CoV (MHV-A59) and used it to study viral replication and dissemination *in vivo*; however, MHV-A59 has a complicated tropism in mice. [@bib12] successfully established a human *dipeptidyl peptidase-4*-knock-in mouse model susceptible to pseudotyped Fluc-expressing MERS-CoV, allowing MERS-CoV to be optically imaged; however, the pseudovirus was unable to replicate, and the authors could only study the entry process. Furthermore, the animal model is not suitable for simulating the pathological CNS symptoms caused by HCoV infection. In the present study, we showed that a BLI-based HCoV-OC43 animal model could be used to test antiviral drug efficacy. CNS luciferase levels accurately represented therapeutic effect, highlighting the potential of the BLI platform to evaluate antiviral drugs for treating HCoV-OC43 infection and its neurological complications by monitoring its replication and dissemination in the same animals in real-time. Although BLI technology is beneficial for studying viral replication and dissemination, it has some inherent limitations. First, hair and organ pigmentation can affect photon transmission; therefore, photon flux from tissues close to the body surface are detected more easily than those from internal organs, with light attenuating at a \~10-fold decrease per cm of tissue ([@bib9]; [@bib8]). This phenomenon explains why we were only able to detect strong signals from the dorsal rather than the ventral side of infected mice. Second, limited biodistribution, rapid metabolic kinetics, and higher background levels restrict the use of BLI for molecular imaging ([@bib5]; [@bib37]; [@bib45]). Therefore, the genetic background of the host should be taken into account, even if they are permissive to the virus. In the present study, signals were only detected in the CNS of BALB/c mice after inoculation, despite the fact that both C57BL/6 and BALB/c mice are permissive to rOC43-ns2DelRluc. This might be due to the bioavailability of the Rluc substrate, which might not be absorbed and transported to the point of infection with Rluc-expressing viruses ([@bib37]). This limitation could potentially be overcome by replacing the Rluc reporter in rOC43-ns2DelRluc with Fluc ([@bib8]; [@bib38]).

CQ has been tested successfully in several animal models and found to protect 5-day-old suckling mice (survival rate: 100%) following administration at 1-day prepartum to pregnant mice infected with HCoV-OC43 ([@bib19]). Moreover, a survival rate of 70% was observed in BALB/c mice infected with avian influenza H5N1 virus following treatment with 50 mg/kg/day CQ ([@bib54]). CQ is widely distributed throughout bodily tissues and fluids, with a higher concentration in the brain than in the plasma. In the present study, *in vivo* data demonstrated that CQ could inhibit HCoV in the CNS of animals. Different mechanisms have been described for the inhibition of viral infection by CQ ([@bib41]); however, the exact mechanisms by which CQ affects HCoV-OC43 in the CNS of animals requires further study.

In summary, we developed a powerful method for real-time monitoring of HCoV-OC43 replication and dissemination in the CNS. To the best of our knowledge, this is the first report on non-invasive BLI in the CNS of living HCoV-infected mice. Furthermore, rOC43-ns2DelRluc-based BLI is a promising platform for non-invasively screening antiviral compounds *in vivo* and developing new therapeutic strategies. This study will contribute to future studies on CoV-host interactions *in vivo,* the screening of broad-spectrum drugs, and new approaches for studying CNS pathologies caused by respiratory viruses.
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